Differences in acute kidney injury ascertainment for clinical and preclinical studies | Zendy

Marco Fiorentino | Zendy; Giuseppe Castellano | Zendy; John A. Kellum | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Differences in acute kidney injury ascertainment for clinical and preclinical studies

Author(s) -

Marco Fiorentino,

Giuseppe Castellano,

John A. Kellum

Publication year - 2017

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfx002

Subject(s) - medicine , acute kidney injury , odds ratio , creatinine , biomarker , confidence interval , blood urea nitrogen , renal function , clinical endpoint , intensive care medicine , oncology , clinical trial , biochemistry , chemistry

Acute kidney injury (AKI) is a common clinical condition directly associated with adverse outcomes. Several AKI biomarkers have been discovered, but their use in clinical and preclinical studies has not been well examined. This study aims to investigate the differences between clinical and preclinical studies on AKI biomarkers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research